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Summary The presence of T lymphocytes in solid tumours may reflect an ongoing immune response against
the transformed cells. We have used polymerase chain reaction (PCR) technology to investigate the T-cell
receptor variable-region gene (V-gene) usage in freshly isolated tumour-infiltrating lymphocytes (TILs) to look
for a possible oligoclonality of T cells in the tumour area. We used 19 different VP-family-specific primers.
Peripheral blood lymphocytes and lamina propria lymphocytes from the same patients were also tested by
PCR. Our results demonstrate a limited heterogeneity in the V-gene usage of TILs from seven patients with
colorectal cancers, suggesting a local antigen-driven immune response at the tumour site.
The existence of tumour-specific antigens has long been ques-
tioned, but recently the first tumour rejection antigen was
identified and cloned from a human malignant melanoma
(van der Bruggen et al., 1991). Several groups have demon-
strated autologous tumour-reactive, MHC-restricted tumour-
infiltrating T lymphocytes (TILs) derived from malignant
melanomas (Herin et al., 1987; Itoh et al., 1988), and similar
results have been obtained with TILs from head and neck
cancers (Yasumura et al., 1993) and ovarian carcinomas
(Ioannides et al., 1993). In vivo, TILs appear to be more
effective in adoptive immunotherapy than autologous
peripheral blood lymphocytes (PBLs) (Rosenberg et al.,
1988), suggestive of a primed population in the tumour area.
Few studies are available on TILs from colorectal car-
cinomas, but a recent report provides evidence for a specific,
MHC-restricted immune response to autologous, human
colon carcinomas (Hom et al., 1993). Furthermore, the
degree of lymphoid infiltration in such tumours is strongly
correlated with the prognosis (Svennevig et al., 1984; Jass,
1986), suggesting that patients can raise a significant immune
response against these tumours.
Finally, gene transfection studies in murine models have
shown that provision of local help in the form of cytokines
(Fearon et al., 1990; Golumbek et al., 1992) can induce
tumour rejection both locally and distantly, and can even
enable the immune system to reject a later challenge with
unmodified (parental) tumour cells.
Thus, a specific immune response can be mounted against
at least some tumours, although insufficient or abrogated in
most cases. Conventional phenotyping of freshly isolated
TILs has shown that the infiltrating cells are predominantly
T cells, which are activated and express the memory pheno-
type (CD45R0+) more often than peripheral blood lympho-
cytes from the same patient (Topalian et al., 1987; Ostenstad
et al., 1994).
If T cells do recognise and react to tumour-specific anti-
gens, a clonal expansion of the tumour-reactive T cells is
expected to be an early event. A clonal expansion of this
kind will be characterised by restricted T-cell receptor (TCR)
variable region gene (V-gene) usage.
In the majority of T cells the TCR is composed of an
o/p-heterodimer, each chain containing a variable and con-
stant region. During T-cell development the genes coding for
the variable regions are created by rearrangement of alterna-
tive gene segments. The functional P-chain gene, for example,
is created by recombination of one of each of at least 106
variable (V), two diversity (D) and 13 joining (J) gene
segments (combinatorial diversity) (Mak, 1993). Imprecise
junction of the different segments (junctional diversity) and
the addition of nucleotides not encoded by either gene seg-
ment (N-region diversity) greatly increase the variability of
the gene product and together with the a-chain constitute the
unique T-cell receptor. The diversity is concentrated in the
putative antigen-binding CDR3-equivalent region, corre-
sponding to the D and J regions (and a small part of the
3'-terminal V regions). The V segments are evolutionarily
related, and can be grouped together as about 20 gene
families.
Preferential expression of certain VP-families in the tumour
area would be suggestive of a clonal expansion of antigen-
specific T cells. Such VP restriction has been described in
many non-malignant disorders, such as allograft rejections
(Ibrahim et al., 1993) and autoimmune diseases (Sioud et al.,
1992; Davies et al., 1993). Limited heterogeneity has also
been demonstrated in IL-2-expanded TILs (Karpati et al.,
1991; Morita et al., 1992). However, the VP repertoire is
influenced by mitogen stimulation in vitro (Wong et al.,
1993), and the culture conditions may favour the selective
outgrowth of certain subpopulations with minor representa-
tion in vivo. Thus, a better image of the in situ VP repertoire
can be obtained by testing the freshly isolated lymphocytes.
A few groups have demonstrated restricted V,B-gene usage in
freshly isolated TILs from malignant melanomas (Nitta et
al., 1991; Ferradini et al., 1993) and hepatocellular car-
cinomas (Weidmann et al., 1992), while other reports con-
clude that the immune response to tumour is extremely
diverse, with no preferential usage of any gene (Ferradini et
al., 1992).
We have investigated the VP-gene usage of freshly isolated
TILs derived from seven different colorectal tumours using
polymerase chain reaction (PCR) and 19 VP-family-specific
primers, and compared this with T cells from PBLs from the
same patients. We have also analysed lymphocytes from the
laminal propria (LPLs) in the unaffected resection margin in
four of these patients.
Materials and methods
Isolation ofcells
Peripheral blood and surgical specimens were obtained from
seven patients with primary adenocarcinoma of the colon or
the rectum.
The lymphocyte preparations were obtained as described
previously (Ostenstad et al., 1994). Briefly, the tumours were
minced and digested enzymatically in complete medium
(RPMI-1640 with 25 mM HEPES buffer and 10% fetal calf
serum, containing 0.05% Collagenase D, 0.002% DNAse
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(Boehringer Mannheim Biochemica, Germany) and 5 mM
calcium chloride. The resultant crude suspension was filtered
through a fine nylon mesh (80gm) to exclude undigested
fragments, washed twice in Hanks' balanced salt solution
(HBSS), and passed over a discontinous density gradient
(Percoll, Pharmacia, Uppsala, Sweden), collecting the lym-
phocytes from the 60%/30% interface and discarding the
debris and dead cells at the top.
One million cells from each compartment were frozen as
pellets for later extraction of total RNA.
Phenotyping
Freshly isolated lymphocytes were suspended in cold HBSS
containing 0.02% sodium azide in V-bottom plates.
Fluorescein-conjugated monoclonal antibodies were added in
1:20 dilutions for staining 30 min on ice. The following
antibodies were used: UCHT-1 (anti-CD3), MT310 (anti-
CD4), DK25 (anti-CD8), HD37 (anti-CD19), UCHL-1 (anti-
CD45R0), ACT-1 (anti-CD25), HLA-DR CR3/43 (reacting
with the common MHC class II P-chain) (all from Dako,
Glostrup, Denmark), and 2H4 (anti-CD45RA) and NKH-1
(anti-CD56) (from Coulter Immunology, Hialeah, FL,
USA).
Analysis was performed using a FACScan flow cytometer
(Beckton Dickinson, Mountain View, CA, USA) and LYSYS
II software.
Preparation ofRNA, cDNA synthesis andpolymerase chain
reaction (PCR) amplification
Total RNA was prepared using guanidium isothiocyanate-
phenol-chloroform extraction (Chomczynski & Sacchi, 1987).
cDNA was synthesised from RNA as described previously
(Sioud et al., 1991). The same amount of cDNA from each
sample was used as template for PCR amplification using a
panel of 19 family-specific oligonucleotides and Cp-primers
with sequences as previously described (Sioud et al.,
1991).
The scope of this investigation was a non-quantitative
search for the relative overrepresentation of certain Vp-
families within each tumour, and each sample therefore
served as its own control. However, in order to be sure that
all the different reactions were set up with the same accuracy,
we also performed co-amplification of the constantly present
Ca-segment in a few samples. The sense and antisense Ca-
primers used were as described previously (Sioud et al.,
1991).
Thirty to forty amplification cycles were performed using a
DNA thermal cycler (Perkin Elmer, Cetus). Each cycle con-
sisted of denaturation at 92°C for 1 min, annealing at 56°C
for 1+ min and extension at 72°C for 2+ min. The PCR
products were separated on a 2% agarose gel, transferred to
nylon membrane, hybridised with 5' 32P-labelled internal Cp-
primer and 5' 32P-labelled antisense Ca-primer and autoradio-
graphed. The autoradiograms were used to identify the Vp-
Cp bands at expected sizes (approximately 600 base pairs)
and the Cm-bands (approximately 140 bp) (Figure 1) PBL
and TIL cDNAs from the same patients were always
prepared, amplified and run in parallel.
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Figure 1 VP-gene products (VP-CP) obtained by amplification of
cDNA from peripheral blood lymphocytes (PBLs), tumour-
infiltrating lymphocytes (TILs) and lamina propria lymphocytes
(LPL). The numbers on top refer to the VP-family-specific
primers used. Co-amplification of the constantly present Ca-
segment was performed as a control. The arrows indicate signals
detectable in the original films.
Results
Phenotypes
As reported previously (Ostenstad et al., 1993), the infil-
trating lymphocytes were predominantly T lymphocytes
(CD3+), with equivalent numbers of CD4+ and CD8+
subsets (Table I). There was a significantly lower number of
NK cells (CD56+) and conversely a higher number of B cells
(CD19+) among TILs. They also appeared activated and
expressed the memory phenotype (CD45R0+) more often
than PBLs from the same patient, suggestive of a primed
population in the tumour area.
T-cell receptor VP-gene usage
We found that PBLs from each of our patients expressed
most of the 19 VP-families, consistent with the expected
polyclonality in this compartment. In contrast, the tumour-
infiltrating lymphocyte (TIL) preparations showed a marked
restriction in the V-gene usage (Figures 1 and 2). In TIL 17
only one VP-family was detected, as indicated by the arrow.
This is strongly suggestive of an overrepresentation of V,3
within this sample. Remarkably, this same family is absent
from the corresponding PBLs (Table II). In TIL 20, four
families are detected, consistent with an overexpression of
these families within the sample.
Our method is only semiquantitative, and comparison
between two samples is difficult. However, if we look at
Table I Phenotypes of freshly isolated lymphocytes
CD45RO/
CD3 CD4 CD8 CD56 CD19 CD45RA CD25 HLA-DR
PBLs 60 42 25 19 7 0.8 10 22
TILs 58 30 22 5** 19* 1.5** 22** 34*
The proportions of different antigens are expressed as a percentage of all mononuclear cells. The
tumour-infiltrating lymphocytes (TILs) are significantly different from the peripheral blood
lymphocytes (PBLs). *P<0.05; **P<0.005.1080 B. 0STENSTAD et al.
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Figure 2 VP-gene products obtained by amplification of cDNA
from peripheral blood lymphocytes (PBLs) and tumour-
infiltrating lymphocytes (TILs) from three patients. The numbers
on top refer to the Va-family-specific primers used. The
autoradiograms were overexposed to visualise all the faint
amplifications, and the arrows indicate every detectable signal.
patient 1, V17 but not V18 is detectable in the TIL prepara-
tion, while V138 is more strongly expressed in the peripheral
blood from the same patient.
Although only three of the patients (8, 17 and 20) had an
obvious oligoclonal pattern in their TIL V-gene usage, the
last four patients also demonstrated a limited heterogeneity
(Table II).
No single gene family was consistently overrepresented in
all the tumours.
Because lymphocytes in the gut mucosa are continuously
exposed to antigens, we asked ourselves if the linited
heterogeneity might be a common feature of lymphocytes
residing in this specialised tissue. To address this question,
we tested the TCR V-gene usage of lymphocytes from the
LPL in the resection margin, away from the tumour, in four
of the patients. An intermediate picture was found, with little
more than half the families expressed (Figure 1 and 3). While
VP-families 11 and 15 were absent from all these samples,
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Figure 3 VP-gene products obtained by amplification of cDNA
from lamina propria lymphocytes (LPLs). The numbers on top
refer to the VP-family-specific primers used. The autoradiograms
were overexposed to visualise all the faint amplifications, and the
arrows indicate every detectable signal.
family 11 was detected in one matched TIL sample (TIL 16),
as well as in another unmatched sample (TIL 11), while 15
was expressed in TIL 21. Four of the families present in TIL
16 lacked the corresponding LPL 16.
This overrepresentation of certain VP-families in TILs
compared with LPLs is also suggestive of a localised clonal
expansion in the tumour area.
Discussion
Much evidence has accumulated during the past few years
supporting the hypothesis of a specific immune response
against malignant tumours. However, most studies so far
have focused on the functional testing of T-cell cytotoxicity
(Herin et al., 1987; Itoh et al., 1988; Yasumura et al., 1993)
or cytokine secretion (Belldegrun et al., 1989; Hom et al.,
1993).
We have used the sensitive PCR technique to investigate
the T-cell receptor variable-region gene (VP-gene) usage of
TILs obtained from seven patients with colorectal tumours
together with PBLs from the same patients. We found a
limited heterogeneity in all the tumour samples, although to
a variable extent. This PCR method is a semiquantitative
approach, and care must be taken in comparing different
samples, but there is an obvious overrepresentation of a few
families within each TIL sample, as indicated in the figures.
The results from the PBL samples indicate that the primers
function well, and should be able to pick up every family
present. Furthermore, a rather high number of amplification
cycles were performed.
Table II T-cell receptor V-gene usage
VP-families
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20
PBL 8 + + + + + + + + + + + + + + + + + + +
PBL 11 + + + + + + + + + + + + + + + + +
PBL 16 + + + + + + + + + + + + + + + + +
PBL 17 + + + + + + + + + + + + + + +
PBL 20 + + + + + + + + + + + + + + + + +
PBL 21 + + + + + + + + + + + + + + + + + +
TIL 8 + +
TiL 11 + + + + + + + + +
TIL 16 + + + + + + + + +
TIL 17 +
TIL 20 + + + +
TIL 21 + + + + + + + +
TIL 22 + + + + + + + +
LPL 16 + + + + + + + + + + +
LPL 17 + + + + + + + + + + + +
LPL 21 + + + + + + + + + + + + +
LPL 22 + + + + + + + + + + +
(+) indicates the families detected in the original films. PBL, peripheral blood lymphocyte; LPL, lamina
propria lymphocyte; TIL, tumour-infiltrating lymphocyte.
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The fact that different sets of families predominate in each
tumour therefore argue against a biased amplification due to
variable quality of the primers. The inter-sample variability
may actually serve as internal controls.
That no single family is consistently overrepresented in all
the tumours may reflect the complexity of the TCR-antigen
interaction. T cells (presumably including TILs) recognise
antigens in the form of short peptides presented in the con-
text of MHC molecules on the target cell. These peptides
may be fragments of mutated gene products in the tumour
cell having a unique sequence. The specific interaction
between tumour cells and T lymphocytes therefore depends
on the presence of immunogenic peptides, suitable antigen-
presenting MHC molecules and the specific T-cell receptor
(TCR).
The variable pattern of gene usage may be explained by
the accumulation of mutations in colorectal tumours (Fearon
& Vogelstein, 1992), which may give rise to a number of
hypothetical T-cell antigens. Any antigenic peptide may also
be more or less well presented in different patients depending
on their HLA type and individual expression of MHC
molecules. Thus, several antigen-MHC combinations may
be present in one tumour, although the host usually responds
to only one of several antigens displayed simultaneously on
the tumour cell surface (immunodominant epitopes) (Urban
et al., 1986).
Finally, both tumour-specific effectors and negative
regulatory T-cell clones may coexist in the same tumour, as
suggested by specific VP-depletion studies (Gelber et al.,
1992). These different subsets may express receptors belong-
ing to different VP-families.
With this complexity in mind, we note that in three out of
seven patients there was definitely an oligoclonal pattern,
with fewer than five families clearly represented. To the best
of our knowledge this is demonstrated here in TILs from
colorectal cancers for the first time.
A limited heterogeneity was also noted in the rest of the
patients, comparing TILs with PBLs. However, the repertoire
in these four patients was nearly as heterogenous as in the
four control samples from tumour-free LPLs. We had ex-
pected a more polyclonal pattern among LPLs. One possible
explanation is that this may be caused by a predominant
non-specific inflammatory response in the neighbouring area.
In TIL 11 and 16 (and to somne extent in TIL 21 and 22) such
an inflammatory response may obscure a possible specific
oligoclonality. It is noteworthy, however, that in one of the
paired LPL/TIL samples (16) V,4, VP6, VP9 and VPI11 were
present in TILs, but not in LPLs. In another matched pair
(21) VP5 and VP15 were present in TILs, while absent in
LPLs. This is also suggestive of possible tumour-reactive
clones.
Taken together, a limited heterogeneity in the VP-gene
usage was found among TILs, consistent with an expansion
of tumour-reactive clones in situ. No single predominant
VP-family was detected in the present tumours, suggesting
the involvement of different antigen-MHC combinations.
Sequence analysis of the fine specificity in the junctional
region may clarify this point.
To better understand the significance of this apparent
restriction, it is necessary to combine this approach of TCR
phenotyping with functional studies at the clonal level.
Monoclonal antibodies against a number of different Vp-
families are now available. In contrast to the PCR approach,
such antibodies can be utilised in the detection and sorting of
viable cells for functional studies, and possibly also in future
for selection of T cells particularly suited for adoptive
immunotherapy. Alternatively, putative suppressor clones
can be depleted.
In conclusion, this study supports the hypothesis that
tumour-specific T lymphocytes reside and expand in the
tumour area, although the response may be directed against
different antigens.
This work was supported by the Norwegian Cancer Society.
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